Find a Physician How to Contribute Affiliated Hospitals Clinical Trials

Search Clinical Trials
Protocol NU UCSF12I01
None Defined

Title Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (124511)
Purpose The purpose of this study is to find out what effects (good and/or bad)the drug combination of Temsirolimus and Sorafenib has on advanced hepatocellular carcinoma (HCC).
Overview HCC is a liver cancer that cannot be removed by surgery. Sorafenib is the standard treatment for HCC. Sorafenib works by turning off some of the chemicals in the tumor cells that let the tumor grow new blood vessels. Temsirolimus works by turning off some of the chemicals that help cells grow and divide. An earlier study (Phase 1) shows promise that the addition of Temsirolimus will make Sorafenib more effective in the treatment of HCC. Temsirolimus is approved by Food & Drug Administration (FDA) for treatment of kidney cancer but it's use in treating HCC is considered experimental.
Who May
be Eligible
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older
  • Participants must have advanced inoperable hepatocellular carcinoma.
  • Participants may not have had prior chemotherapy for their HCC.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Description of Treatment Participants will take both Sorafenib and Temsirolimus for a 28 day cycle. Particpants will be assessed for results after each cycle. Treatment will continue for participants until their disease worsens, they experience unacceptable side effects, or the study doctor decides it is in their best interest to be removed from the study.

Clinical trial availability changes frequently. Please check this site for new or updated trials that pertain to you.
If you have questions about current or future trials, contact the Cancer Center at 866-LURIE-CC (866-587-4322) or
About Us | Job Opportunities | Northwestern University | Maps & Directions | Contact Us
© Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Clinical Cancer Center: 866.LURIE.CC || Chicago Administrative Office: 312.908.5250.
Contact us with questions at:
National Comprhensive Cancer Network National Cancer Institute You Tube Facebook